Cathay Biotech Inc. (SHA:688065)

Market Cap	28.13B -18.9%
Revenue (ttm)	3.59B +9.1%
Net Income	637.00M +7.2%
EPS	0.88 -3.7%
Shares Out	720.66M
PE Ratio	44.16
Forward PE	34.58
Dividend	0.45 (1.15%)
Ex-Dividend Date	Jul 29, 2026

Volume	5,195,217
Open	38.20
Previous Close	39.21
Day's Range	38.01 - 39.60
52-Week Range	35.44 - 64.50
Beta	0.50
Analysts	Strong Buy
Price Target	55.09 (+41.15%)
Earnings Date	Oct 31, 2026

About Cathay Biotech

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company’s products are used in textiles, pharmaceuticals, automobiles, ...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 1,844
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688065

Financial Performance

In 2025, Cathay Biotech's revenue was 3.30 billion, an increase of 11.40% compared to the previous year's 2.96 billion. Earnings were 560.72 million, an increase of 14.68%.

Analyst Summary

According to 2 analysts, the average rating for 688065 stock is "Strong Buy." The 12-month stock price target is ¥55.09, which is an increase of 41.15% from the latest price.

Price Target

¥55.09

(41.15% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error